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Abstract
Background T regulatory cells (Tregs) are known to neg-
atively control immune response. The frequency of these
cells was inversely correlated with clinical outcomes of
breast cancer. CD19?CD24hiCD38hi cells also play a crit-
ical role in inflammation and autoimmune disease. How-
ever, their function in tumor immune response is less
studied. In this study we aimed to determine the role of
CD19?CD24hiCD38hi cells and some other clinicopatho-
logical variables in increasing the proportion of Tregs in
breast cancer patients.
Methods We selected 47 patients with invasive ductal
breast carcinoma and 50 healthy controls and obtained their
blood samples.
Results The proportion of circulating CD4?CD25?Foxp3?
Tregs and CD19?CD24hiCD38hi cells was significantly
increased in breast cancer patients. We also found that
increased proportion of Tregs in breast cancer is correlated
with HER2 amplification, advanced clinical stages, serum
TGF-b1 and increased CD19?CD24hiCD38hi cells in the
peripheral blood.
Conclusion Altogether, our data suggest that as much as
Tregs, CD19?CD24hiCD38hi B cells could also have a part
in the suppression of immune response in breast cancer.
Keywords Breast cancer  T regulatory cells 
CD19 ? CD24 ? CD38 ? B cells  Clinicopathological
variables
Introduction
Breast cancer, a heterogeneous and complex disease, is
currently the world’s most frequently diagnosed cancer
among women [1]. Although the incidence of breast cancer
has increased constantly in developed countries over the
past few decades, the mortality caused by breast cancer has
decreased in recent years, partly because of improved
diagnostic and therapeutic techniques and also better
understanding of the pathogenesis of the disease [2]. The
prognosis of the disease is strongly associated with tumor
stage [3] and could also be predicted by biological char-
acteristics of tumor cells, including expression of hormone
receptors (HR) and human epidermal growth factor
receptor 2 (HER2) [4]. However, it is increasingly realized
that tumor cell’s surrounding microenvironment also plays
an important role in the disease progression [5].
Regulatory T cells (Tregs) are a particular subset of
CD4? T cells with expression of CD4?CD25?FoxP3? and
comprise about 5% of CD4? T cells in the peripheral blood
[6, 7]. Tregs induce immune tolerance and they were
shown to inhibit immune cells to secrete inflammatory
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cytokines and suppress autoimmunity in many autoimmune
diseases [8]. In addition, their ability to mediate suppres-
sion of cancer’s immune response is increasingly recog-
nized [9, 10] and studies have found that Tregs play
important roles in tumor scape [11]. Elevated proportion of
Tregs is present within tumors, lymph nodes and peripheral
blood of various types of solid and hematologic cancers
including breast cancer [12, 13]. Besides, frequency of
CD4?CD25?FoxP3? cells have been demonstrated to be
inversely correlated with the clinical outcomes of breast
cancer [13].
Transforming growth factor-b1 (TGF-b1) plays a cru-
cial role in suppressing immune cells. It takes part in
inducing the differentiation of Tregs [14]. TGF-b1 is
secreted by many cells and it is also known as the main
cytokine produced by Tregs. Studies have revealed that
TGF-b1 implicates in tumor progression including breast
cancer [13, 15].
The pivotal role of regulatory T cells in suppressing
antitumor immune response has been extensively studied
and is almost accepted. In addition to Tregs, there is also a
subset of B cells described with regulatory capacity, con-
firmed as regulatory B cells [16, 17]. The identification of
Bregs in human is controversial. Studies have reported
regulatory functions for different B cell subsets. Blair and
colleagues have described Bregs with CD19?CD24hi-
CD38hi phenotype that suppress the differentiation of T
cells via secretion of IL-10 [18]. This suppressive effect
could be mediated through induction of FoxP3 expression
in CD4?CD25? T cells [18, 19]. Further evidences sug-
gested that these Bregs play an essential role in patho-
genesis of autoimmune diseases [16]. Although Bregs have
been extensively studied in these diseases, there is a little
known about their role in human cancer. Some studies have
suggested their role in lymphomas and skin carcinomas
[20, 21]. A recent study also described the role of
CD19?CD24hiCD38hi cells in suppressing tumor immunity
in gastric cancer [22].
In this study, we aimed to compare breast cancer
patient’s T and B regulatory cells of peripheral blood
with healthy individuals and assess the association
between different clinicopathological variables including
CD19?CD24hiCD38hi B regulatory cells with the pro-
portion of T regulatory cells in the peripheral blood as a
poor prognostic marker in breast cancer. To our
knowledge, this is the first study that investigates the
frequency of CD19?CD24hiCD38hi B regulatory cells in
breast cancer.
Materials and methods
Patients and controls
In this cross-sectional study, 47 patients diagnosed with
invasive ductal breast carcinoma were enrolled between
December 2014 and December 2016. Fifty age- and BMI-
matched females were recruited as healthy controls.
Peripheral blood samples were obtained from breast cancer
patients before receiving any chemotherapy or
immunotherapy medications. HER2 status was determined
by the latest version of ASCO/CAP HER2 testing guideline
update [4]. Nottingham criteria were used to describe his-
tological grade [23, 24]. Also the tumor size was deter-
mined by the TNM staging according to the new staging
system of the American Joint Committee on Cancer/In-
ternational Union against Cancer (AJCC/UICC) [25].
Individuals with a past history of allergic or autoimmune
diseases were excluded from the study. The study was
approved by the ethics committee of Bushehr University of
medical sciences.
Analysis of CD41CD251Foxp31 T cells
and CD191CD24hiCD38hi B cells
Peripheral blood (PB) from all patients and healthy con-
trols was obtained, collected in EDTA-containing tube, and
transferred immediately to the flowcytometry laboratory
for staining and further analyses. The flowcytometric
analysis was performed according to the manufacturer’s
instructions (BD Biosciences, USA). Peripheral blood
mononuclear cells (PBMC) were stained for cell surface
molecules to determine the number of cells with Treg and
CD19?CD24hiCD38hi cells phenotype using anti-CD4-
PerCP-Cy5.5 and anti-CD25-FITC antibodies, anti-CD19-
PerCP-Cy5.5, anti-CD24-PE, and anti-CD38-FITC (BD
Biosciences, USA), followed by paraformaldehyde (1%)
fixation and intracellular staining using an anti-FoxP3-PE
antibody (BD Biosciences, USA) [26]. The data were
analyzed with a 3-color FACSCalibur (BD Biosciences,
USA), using CellQuest software (Becton–Dickinson,
USA). The proportion of Treg cells was calculated as the
percentage of CD25?FoxP3? cells within the CD4? lym-
phocyte, and the proportion of CD19?CD24hiCD38hi cells
was calculated as the percentage of CD24?CD38? cells
within the CD19? lymphocyte gate. Two typical results of
FACS scan from Treg and CD19?CD24hiCD38hi cells are
depicted in Fig. 1.
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Serum TGF-b1 and IL-10 analysis
The serum concentrations of TGF-b1 and IL-10 were
measured using an ELISA kit in accordance with the
manufacturer’s protocol (Boster Biological Technology
Co., Wuhan, China). Samples (in duplicate) were incubated
on array plates. The levels of cytokines were quantified by
reference to standard curves. Determinations were per-
formed in duplicate and the results were expressed as pg/
ml.
Statistical analysis
T test was used to compare quantitative variables across
the two groups. The significance of the T regulatory
cell’s differences between multiple groups was evaluated
by Kruskal–Wallis test. Spearman correlation analysis
was employed to study the relationships among
CD19?CD24hiCD38hi cells, TGF-b, age, and Tregs.
Probability values \5% were considered statistically
significant.
We used a generalized linear model for estimating the
adjusted influence of each clinicopathological variable
(reference variable) on Treg percentage (dependent
variable).
Results
There were no significant age or BMI differences between
patients and control groups (P = 0.18, 0.98) (Table 1).
The proportion of T regulatory cells, B regulatory cells,
and serum concentration of TGF-b1 were determined to be
increased in Breast cancer group compared with the control
group (Table 2).
Since the amount of CD4?CD25?FoxP3? T cells was
shown to negatively impact breast cancer prognosis [13],
we also calculated the relation of different clinicopatho-
logical variables with T regulatory cells. Treg percentage
of patients with different clinical stages, histological
grades, HER2 amplification, and lymphovascular invasion
status were calculated (Fig. 2). Patients with advanced
Fig. 1 T and B cell composition in peripheral blood. SSC (side
scatter), FSC (Forward Scatter), R1, R2 (regions). a Representative
gating strategy for Treg cells in the peripheral blood, Shows the
population of CD4?CD25?FoxP3? cells in the test sample. b Repre-
sentative gating strategy for B cells in the peripheral blood shows the
population of CD19?CD24hiCD38hi cells in the test sample
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clinical stages and histological grades and positive HER2
amplification were more likely to have increased percent-
age of peripheral blood Treg cells (P\ 0.05). Also there
were no significant differences in the serum TGF-b1 and
IL-10 of patients with or without HER-2 amplification
(P = 0.61, 0.89) (see Fig. 3).
The percentage of T regulatory cells had a significant
correlation with the percentage of CD19?CD24hiCD38hi B
cells in the peripheral blood (q = 0.715, P\ 0.001) and
the serum levels of TGF-b1 (q = 0.815, P\ 0.001) in
breast cancer patients, while no correlation was found
between Tregs and age in patients (P[ 0.05).
After calculating the relation of each variable with the
percentage of Tregs one by one, a generalized linear model
was used to reveal the adjusted impact of each variable on
Tregs proportion (Table 3). Regarding the fact that all
variables may affect each other and therefore, it may change
the impact of the target variable on Tregs percentage. As you
see in Table 3, advanced clinical stage, HER2 amplification,
Serum TGF-b, and the percentage of peripheral blood
CD19?CD24hiCD38hi cells are correlated with the propor-
tion of T regulatory cells in the peripheral blood (see Fig. 4).
Discussion
Tregs are believed to inhibit productive tumor immune
surveillance and the inflammation caused by Tregs seems
to promote tumorigenesis [27]. In breast cancer patients
increased Tregs independently predict a worse clinical
outcome. However, the mechanism and conditions through
which Tregs are increased are less known [10]. CD19?-
CD24hiCD38hi cells play a key role in inflammation pro-
cess and autoimmune diseases; however, the role of
CD19?CD24hiCD38hi cells in the development of human
cancer is less studied [28]. In this study, first we focused on
breast cancer and examined the percentage of T and B
regulatory cells and compared them with healthy individ-
uals. As we expected and similar to the result of other
studies [12, 29], the breast cancer patients had a signifi-
cantly elevated percentage of circulating CD4?CD25?-
FoxP3? T cells compared to healthy controls. We also
observed this elevation in the percentage of circulating
CD19?CD24hiCD38hi B cells compared to healthy con-
trols. In addition to Tregs, this result could provide an
important support for the role of CD19?CD24hiCD38hi
cells in breast cancer and indicate that CD19?CD24hi-
CD38hi cells may also be responsible for the tolerogenic
immune response in breast cancer.
HER2 amplification is regarded as a poor prognosis
factor in breast cancer, which could increase the
Table 1 Demographic and clinical characteristics of breast cancer
patients
Median age (range) 45.2 (30–61)
Median BMI 26.9
Positive breast cancer family history 17 (36.1%)
HER2
Positive 18 (38.3%)
Negative 29 (61.7%)
IHC status
0/?1 19 (40.4%)
?2 16 (34%)
?3 12 (25.5%)
Estrogen receptor
Positive 42 (89.4%)
Negative 5 (10.6%)
Progesterone receptor
Positive 39 (83%)
Negative 8 (17%)
T stage
T1 17 (36.2%)
T2 23 (48.9%)
T3 7 (14.9%)
N stage
N0 19 (40.4%)
N1 19 (40.4%)
N2 9 (19.1%)
Clinical stage
I 11 (23.4%)
II 24 (51.1%)
III 12 (25.5%)
Histological grade
G1 12 (25.5%)
G2 22 (46.8%)
G3 13 (27.7%)
Lymphovascular invasion
Positive 18 (38.3%)
Negative 29 (61.7%)
Table 2 Tregs,
CD19?CD24hiCD38hi cells,
TGF-b1 and IL-10 status in
study subjects
Breast cancer patients Healthy controls P value
CD4?CD25?FoxP3? cells 7.29% 4.99% <0.001
CD19?CD24hiCD38hi cells 10.43% 6.88% <0.001
Serum TGF-b1 150 pg/ml 67 pg/ml 0.017
Serum IL-10 83 pg/ml 37 pg/ml <0.001
Significant P values are shown in bold
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probability of differentiation and metastasis of tumor [30].
Previous studies have shown an increased circulating Tregs
in HER2 amplified patients [12, 29]. In this study, we also
observed a significant increase in circulating Tregs of
HER2 amplified patients. This increased population of
regulatory T cells in HER2 positive patients causes a
suppressed immune response against tumor and could be an
explanation for the poor prognosis of these patients.
We also observed an elevation of circulating Tregs in
stages II and III in comparison with stage I breast cancer
patients. A recent study has found that tumor-infiltrating
Tregs had a higher frequency in stage III of breast cancer
which suppresses the inflammation caused by CD8? cells
[31]. Since the survival rate of breast cancer patients is
strongly associated with the tumor stage [3], these data also
suggest a more tolerogenic immune profile in advanced
stages of breast cancer.
Although crude data suggesting a higher Treg level in
advanced grades, was because of the association of this
variable with tumor clinical stage and HER2 amplification
[3, 32]. Another study also demonstrated that there is no
association between circulating Tregs and tumor grade
[12]. Since there was a low population of patients with
negative hormone receptor and it was not statistically
valuable, we did not include hormone receptors in our
model analysis.
A variety of mechanisms have been proposed by which
Treg cells mediate inhibition of both CD4? and CD8?
effector T cells, including cytokines such as TGF-b and
IL-10 [33]. Bregs are also capable of directly inducing
anergy of Th1 cells, CD8, and CD4 T cells [34] or
indirectly by converting Tregs [19, 22]. Some studies
indicated that the Tregs immunosuppressive role in
tumors is mediated by Bregs [35]. In this study we
observed that increased CD19?CD24hiCD38hi B cells
positively correlate with levels of circulating Tregs. This
result could support the hypothesis that CD19?CD24hi-
CD38hi cells are inducing their immunosuppressive
effects through increasing circulating Tregs in breast
cancer. A recent study showed a positive correlation
between CD19?CD24hiCD38hi cells and tumor-infiltrating
CD4?FoxP3? T cells in a TGF-b dependent way in
gastric cancer patients and concluded that CD19?-
CD24hiCD38hi cells involve in gastric cancer immune
scape [22]. In our study a significant correlation was
found between serum TGF-b and Tregs which suggests
that the increase in circulating Tregs may be TGF-b
dependent in breast cancer patients. Previous studies
mentioned the role of TGF-b in developing Tregs through
expression of Foxp3 in CD4? cells [36] and this corre-
lation confirms these results.
Some limitations were observed in this study, like the
complex procedures of flowcytometry and also the fact that
Fig. 2 The proportion of CD4?CD25?FoxP3? and CD19?CD24hiCD38hi cells in Breast cancer patients and healthy controls
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we intended to gather blood samples before any treatment
was conducted.
In conclusion, our results show that CD19?CD24hi-
CD38hi cells might be involved in the systemic suppression
of breast cancer’s immune response, whether directly or
through increasing the proportion of circulating Tregs.
Also advanced TNM stage and HER2 amplification are
other conditions in which breast cancer patients have a high
Fig. 3 The percentage of T regulatory cells of breast cancer patients with different; a clinical stages, b histological grades, c HER2 amplification
status, d lymphovascular invasion status
Table 3 Generalized linear
model for Tregs and the impact
of clinicopathological variables
Adjusted impact (95% CI) P value
Clinical stage (I, II) 0.44 (0.00–0.88) 0.051
Clinical stage (I, III) 1.15 (0.50–1.80) <0.001
Histological grade (G1, G2) 0.28 (-0.16 to 0.74) 0.216
Histological grade (G1, G3) 0.30 (-0.24 to 0.85) 0.281
HER2 status (HER2-, HER2?) 0.58 (0.21–0.96) 0.002
LVI status (-, ?) 0.06 (-0.27 to 0.40) 0.717
CD19?CD24hiCD38hi cells 0.21 (0.04–0.37) 0.012
TGF-b 0.00 (0.00–0.00) 0.019
IL-10 0.00 (0.00–0.00) 0.705
Age 0.00 (-0.02 to 0.02) 0.773
Significant P values are shown in bold
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proportion of circulating Tregs. Of course, more studies
should explore the underlying mechanisms that increase
the circulating and tumor infiltrating Tregs and investigate
the possible role of Tregs in a worse clinical outcome in
breast cancer.
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